Prothena | PRTA - 现金及等价物



金融业
股票价格
USD
资产
USD 302.58M
现金及等价物
USD 288.19M
销售成本
USD 28.94M
流动资产
USD 292.01M
流动负债
USD 11.66M
债务
USD 7.65M
EBIT
USD 25.79M
EBITDA
USD 25.98M
员工
163
EPS每股收益
USD 0.6
股本和储备
USD 286.89M
销售毛利
USD 51.08M
债务利息支出
USD 302.58M
利息收入
USD 2.42M
贷款资金
USD 0
市值
USD 520.6M
净收入
USD 32.72M
营业费用
USD 25.29M
营业利润
USD 25.79M
普通股股本
USD 53.08M
PE价格收益
22.11
税前利润
USD 32.72M
销售收入
USD 51.08M
销售和管理费用
USD 12.67M
贸易债权人
USD 1.94M
应收帐款人
USD 5.16M


现金及等价物 更改 日
Acadia Pharmaceuticals USD 956.47M 105.02M 2026-06
Agios Pharmaceuticals USD 99.65M 13.95M 2026-06
Akebia Therapeutics USD 155.55M 7.1M 2026-06
ALKERMES USD 511.53M 159.98M 2026-06
Alnylam Pharmaceuticals USD 1.71B 2.46M 2026-06
Amgen USD 13.99B 1.95B 2026-06
Biogen USD 1.28B 2.1B 2026-06
BioMarin Pharmaceutical USD 874M 1.35B 2026-06
Exelixis USD 281.45M 55.3M 2026-06
Immunic USD 186.63M 171.15M 2026-03
Incyte USD 3.98B 33.45M 2026-06
Ionis Pharmaceuticals USD 350.06M 1.57B 2026-06
MacroGenics USD 113.91M 47.39M 2026-06
Nektar Therapeutics USD 149.58M 134.46M 2026-03
Neurocrine Biosciences USD 332.4M 65.9M 2026-06
Prothena USD 288.19M 41.27M 2026-06
Regeneron Pharmaceuticals USD 2.46B 506.8M 2026-06
Ultragenyx Pharmaceutical USD 125M 50M 2026-06
Vertex Pharmaceuticals USD 7.85B 605.7M 2026-06